Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06308731
Other study ID # 23-26
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 19, 2024
Est. completion date July 1, 2024

Study information

Verified date March 2024
Source Lindenwood University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate acute changes in rates of fat oxidation during exercise with and without the ingestion of a caffeine-based energy drink.


Description:

This study aims to investigate the impact of a caffeinated energy drink on cognitive function and exercise performance in healthy adults. The research will employ a randomized, double-blind, placebo-controlled, crossover design involving 15 participants. Initial screening includes health assessments and completion of a health history questionnaire, as well as a VO2peak assessment. Participants will replicate their diet before every study visit. Subsequent visits involve baseline assessments, ingestion of either a placebo or a caffeinated energy drink, followed by cognitive tests and a cycling exercise bout at moderate intensity, followed by a exercise performance cycling time trial. Measurements, including heart rate, perceived exertion, blood samples, and expired gases, will be collected during and after exercise. The study will have two identical testing visits, separated by at least a week, with participants consuming different beverages to assess their impact on cognitive function and exercise performance.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date July 1, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Male or female participants between 18 - 50 years of age - Signed informed consent - Healthy defined as currently not being treated for an active cardiac, pulmonary, metabolic, immunological, neurological, respiratory, orthopedic, musculoskeletal, psychiatric, or reproductive disease or disorder. With the research team and principal investigator's discretion, some ongoing treatments will be permitted if a determination is made that the treatment will not increase the risk of study participation and the treatment will not confound with desired study outcomes - Physically active which is defined as performing aerobic or resistance-based physical exercise between 2 and 5 times per week - Moderate caffeine users (~300 mg/day) - Body mass index values will range from >24.0 to < 31.9 kg/m2. The average body mass index for the entire study cohort will be less than 31.99 kg/m2. As such, an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 31.99 kg/m2 - Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures Exclusion Criteria: - Body mass index > 31.9 kg/m2 - Positive medical history and/or is currently being treated for some form of heart or cardiovascular, neurological impairment, disease or condition, immune disorder or disease, thyroid disease, kidney disease, renal failure, regular dialysis, liver disease, or other diagnosed hepatic impairment - Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL) - Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year - History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit). - Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) - Currently prescribed statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha-blockers, Vasodilators, etc.) or any other medication at the discretion of the principal investigator - Current smoker (>10 cigarettes per day) - Participants who are lactating, pregnant, or planning to become pregnant - History of alcohol or substance abuse in the 6 months prior to screening - Receipt or use of an investigational product in another research study within 60 days of beginning the study protocol - Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data - Extensive travel (>1 month) that will disrupt the original outline of the study protocol

Study Design


Intervention

Dietary Supplement:
Caffeine-Based Energy Drink
Energy drink with 200 mg caffeine
Other:
Placebo
Placebo

Locations

Country Name City State
United States Exercise and Performance Nutrition Laboratory Saint Charles Missouri

Sponsors (1)

Lead Sponsor Collaborator
Lindenwood University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Impact of a caffeine-based energy drink ingestion on adverse events Self-reported adverse events 3 weeks
Other Impact of a caffeine-based energy drink ingestion on heart rate Heart rate (bpm) 3 weeks
Other Impact of a caffeine-based energy drink ingestion on blood pressure Blood Pressure (mmHg) 3 weeks
Primary Impact of a caffeine-based energy drink ingestion on fat oxidation rates during exercise. Fat oxidation rate (grams/min) during exercise 150 minutes during exercise
Secondary Impact of a caffeine-based energy drink ingestion on energy expenditure rates during exercise. Energy expenditure (kcals/min) 150 minutes during exercise
Secondary Impact of a caffeine-based energy drink ingestion on carbohydrate oxidation during exercise Carbohydrate oxidation rates (grams/min) 150 minutes during exercise
Secondary Impact of a caffeine-based energy drink ingestion on plasma glycerol concentration Plasma glycerol concentration 150 minutes after intervention ingestion
Secondary Impact of a caffeine-based energy drink ingestion on plasma free fatty acid concentration Plasma free fatty acid concentration 150 minutes after intervention ingestion
Secondary Impact of a caffeine-based energy drink ingestion on ratings of perceived exertion Rating of Perceived Exertion (RPE) scale 150 minutes after intervention ingestion
Secondary Impact of a caffeine-based energy drink ingestion on exercise performance Cycling time trial 150 minutes after intervention ingestion
Secondary Impact of a caffeine-based energy drink ingestion on reaction time Simple/ choice reaction time 150 minutes after intervention ingestion
Secondary Impact of a caffeine-based energy drink ingestion on trail making test performance Trail making test 150 minutes after intervention ingestion
Secondary Impact of a caffeine-based energy drink ingestion on Cognition Serial 7 Cognitive processing test 150 minutes after intervention ingestion
See also
  Status Clinical Trial Phase
Withdrawn NCT04540523 - Home-Based Exergaming Intervention N/A
Suspended NCT01212029 - Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging N/A
Enrolling by invitation NCT05273970 - Electrochemical and Electrophysiological Study N/A
Recruiting NCT05227352 - Bio-Experiential Spaces for Mental Health in Healthworkers N/A
Completed NCT02671149 - The Effect of Small Changes in Hydration on Cognition N/A
Completed NCT01333306 - Enhancing Cognitive Training Using tDCS Phase 1
Recruiting NCT05542199 - Nutrition for Brain and Body Health (BB-Health) Feasibility Trial N/A
Recruiting NCT06254638 - Effectiveness of a Multicomponent Intervention to Promote Physical Activity Levels During the School Day (MOVESCHOOL) N/A
Recruiting NCT05998096 - A Randomized Study to Examine the Ability of a Caffeine-Based Energy Drink to Impact Energy Expenditure, Fat Oxidation, Reaction Time, and Other Perceptual Indicators N/A
Recruiting NCT06331286 - The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity N/A
Withdrawn NCT03224559 - Applying Neuromodulation to Accelerate Training Effects
Completed NCT03129048 - Mediterranean Diet, Weight Loss, and Cognition in Obese Older Adults N/A
Recruiting NCT05394363 - Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Suspended NCT05107947 - Light in Frail Elderly - the Effect of a Dynamic Light for Sleep and Circadian Rhythm N/A
Recruiting NCT05372172 - Tennessee Alzheimer's Project
Recruiting NCT05132517 - Magnesium and Cognition After Stroke
Recruiting NCT05992571 - Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity N/A
Recruiting NCT06097182 - Postbiotic Intervention for Acute Stress Management N/A
Completed NCT01223404 - Nicotinic Modulation of the Default Network N/A
Completed NCT00687102 - Cognition in the Study of Tamoxifen and Raloxifene Phase 3